Nano-enabled Peptide Pills

纳米肽丸

• 批准号: 101163
• 金额: $ 54.17万
• 依托单位: NANOMERICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101163
• 关键词: Nano; enabled; Peptide; Pills

An estimated 70 - 105 million Americans and around 20% of European adults suffer from severe chronic pain caused by non-malignant (e.g., HIV, post-herpetic or diabetic neuropathy, arthritis and lower back pain) and malignant (70%-90% of advanced cancer cases) conditions. Current therapies are inadequate in 75% of cases of chronic non-malignant pain and cause side effects in 80% of opioid treated patients; side effects include constipation, nausea, breathing problems addiction and accidental overdose. In 2006, 250,000 US patients required emergency hospital admission for pain drug related complications. We have developed a new nanomedicine based pain drug which is effective in animal studies and works when taken by mouth or by injection. As we are targeting a different receptor to conventional pain drugs, the drug is predicted to have fewer side effects. The compound we are developing does not work without it being put in nanoparticles.

据估计，7000万至1.05亿美国人和约20%的欧洲成年人患有由非恶性肿瘤（例如，艾滋病毒、疱疹后或糖尿病性神经病变、关节炎和下背痛）和恶性（70%-90%的晚期癌症病例）疾病。目前的治疗方法在75%的慢性非恶性疼痛病例中不足，并在80%的阿片类药物治疗患者中引起副作用;副作用包括便秘，恶心，呼吸问题成瘾和意外过量。2006年，250，000名美国患者因止痛药相关并发症需要急诊入院。我们已经开发出一种新的基于纳米医学的止痛药，它在动物研究中有效，口服或注射都有效。由于我们针对的是传统止痛药的不同受体，因此预计该药物的副作用较少。我们正在开发的化合物如果不放入纳米颗粒中就不会起作用。